Warning: The NCBI web site requires JavaScript to function. more...
Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G.
Breast Cancer Res. 2008;10(5):R81. Epub 2008 Sep 29.
Related citations
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J, Ahnström Waltersson M, Fornander T, Skoog L, Nordenskjöld B, Stål O.
Oncogene. 2007 Oct 25;26(49):6997-7005. Epub 2007 May 7.
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
Breast Cancer Res. 2008;10(5):R88. Epub 2008 Oct 17.
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.
J Natl Cancer Inst. 2006 May 17;98(10):671-80.
Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer.
Lundgren K, Tobin NP, Lehn S, Stål O, Rydén L, Jirström K, Landberg G.
J Mol Diagn. 2011 May;13(3):340-51.
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG.
Breast Cancer Res Treat. 2010 Jun;121(2):347-54. Epub 2009 Jul 28.
Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL.
Clin Cancer Res. 1996 Jul;2(7):1177-84.
Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H.
Am J Pathol. 2003 Sep;163(3):985-92.
[Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
Mrhalová M, Kodet R, Strnad P.
Cas Lek Cesk. 2002 Nov 8;141(22):708-14. Czech.
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JF, Nicholson RI, Sutherland RL.
Oncogene. 1998 Aug 27;17(8):1053-9.
Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.
Dedes KJ, Lopez-Garcia MA, Geyer FC, Lambros MB, Savage K, Vatcheva R, Wilkerson P, Wetterskog D, Lacroix-Triki M, Natrajan R, Reis-Filho JS.
Breast Cancer Res Treat. 2010 Dec;124(3):653-66. Epub 2010 Mar 6.
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer.
Gibcus JH, Menkema L, Mastik MF, Hermsen MA, de Bock GH, van Velthuysen ML, Takes RP, Kok K, Alvarez Marcos CA, van der Laan BF, van den Brekel MW, Langendijk JA, Kluin PM, van der Wal JE, Schuuring E.
Clin Cancer Res. 2007 Nov 1;13(21):6257-66.
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
Jirström K, Stendahl M, Rydén L, Kronblad A, Bendahl PO, Stål O, Landberg G.
Cancer Res. 2005 Sep 1;65(17):8009-16.
Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D.
Gynecol Oncol. 2006 Feb;100(2):264-70. Epub 2005 Oct 19.
MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer.
Janssen JW, Cuny M, Orsetti B, Rodriguez C, Vallés H, Bartram CR, Schuuring E, Theillet C.
Int J Cancer. 2002 Dec 20;102(6):608-14.
Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma.
Greer RO Jr, Said S, Shroyer KR, Marileila VG, Weed SA.
Oral Oncol. 2007 Sep;43(8):735-41. Epub 2006 Nov 17.
Cyclin D1, EMS1 and 11q13 amplification in breast cancer.
Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL.
Breast Cancer Res Treat. 2003 Apr;78(3):323-35. Review.
CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei.
Bautista S, Theillet C.
Genes Chromosomes Cancer. 1998 Aug;22(4):268-77.
EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R, Sutherland RL.
Oncogene. 1997 Sep 25;15(13):1617-23.
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL.
Clin Cancer Res. 2011 Apr 1;17(7):2024-34. Epub 2011 Feb 23.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on